Malignant Bowel Perforation
On this page
Direct answer
Free air under the diaphragm in a patient with known advanced cancer is a different disease from perforated appendicitis: malignant bowel perforation — through a tumour, proximal to an obstructing tumour, or from treatment effects such as bevacizumab — carries very high mortality, and management is shaped as much by prognosis as by anatomy. The options run from resection with stoma (Hartmann's-type procedures for colorectal perforation), through palliative diversion or drainage alone, to conservative comfort-focused care; and one diagnosis must always be considered before the knife: lymphoma of the bowel, whose perforation is treated like other lymphoma emergencies — biopsy and chemotherapy, not heroic resection, unless peritonitis forces a damage-control operation.
What you must remember
- Mechanisms: perforation directly through a necrotic tumour (colorectal most common, also lymphoma, gastrointestinal stromal tumours, melanoma metastases); perforation of the caecum proximal to a distal obstructing cancer (closed-loop physiology with a high mortality); and treatment-related perforation from anti-vascular endothelial growth factor agents such as bevacizumab.
- Presentation spectrum: free perforation with generalised peritonitis and pneumoperitoneum; sealed perforation presenting as an abscess or mass (commoner in right-sided and slow tumours); and chronic contained perforation with fistulation to bladder or skin.
- Imaging: erect chest radiograph (free subdiaphragmatic air) and contrast CT, which localises the perforation and defines tumour burden (liver metastases, carcinomatosis, ascites) — findings of carcinomatosis change the operative plan.
- Operative principles: source control at the least physiological cost — resection with end stoma (classically Hartmann's for rectosigmoid) rather than primary anastomosis in an unprepared, contaminated, malnourished cancer patient; defunctioning stoma or drainage alone when the abdomen is hostile or the disease end-stage; damage-control principles in the crashing patient.
- Lymphoma caution: primary gastrointestinal lymphoma (ileocaecal region classically) can perforate spontaneously or during chemotherapy-induced regression — extensive resection does not improve lymphoma outcomes, so the surgical role is limited to treating the perforation and securing tissue.
- Postoperative and palliative planning: goals-of-care conversations before theatre when possible; oncology involvement for later treatment; and recognition that perforation in end-stage disease may appropriately be managed with antibiotics and comfort alone.
- Mortality context: perforated colorectal cancer presenting emergently carries substantially higher mortality than elective resection — say "high-risk" without inventing precise percentages.
How to work through it
A 70-year-old man on palliative chemotherapy for metastatic colon cancer presents with sudden severe abdominal pain and a rigid abdomen; the erect chest radiograph shows free air. The first triage is physiological: he is septic and peritonitic, so theatre is unavoidable — but the operation is planned as source control, not cancer surgery. Laparotomy finds a perforated sigmoid tumour with faecal contamination and multiple liver metastases. The procedure is a Hartmann's resection (rectosigmoid removed, end colostomy, rectal stump closed) — no anastomosis in a contaminated abdomen in a malnourished patient, and no expectation of reversal given the prognosis. If instead the CT had shown a sealed paracolic abscess from a right-sided tumour in a stable patient, the sequence changes: percutaneous drainage, staging, then definitive (potentially curative) resection after optimisation. The third branch: a young man with a terminal ileal mass and perforation, where frozen section suggests lymphoma — the surgeon controls the perforation and obtains adequate tissue, but definitive treatment is chemotherapy, and over-resection adds morbidity without benefit. In every branch, one decision stands before the rest: whether the patient is being treated to live longer, to live better, or to die comfortably — documented before the abdomen is opened.
Where students slip
The reflex answer "resection and primary anastomosis" ignores the contamination-nutrition-prognosis triad that pushes toward a stoma; similarly, "always operate" ignores the legitimate palliative pathway in end-stage disease, which examiners increasingly expect candidates to articulate rather than dodge. The lymphoma trap deserves specific preparation: a stem describing a small bowel or ileocaecal perforation in a younger patient, with a mass and B symptoms, invites an answer built around tissue diagnosis — and the classical teaching that lymphoma can perforate during chemotherapy-induced regression. Bevacizumab-associated perforation is a modern favourite: candidates should connect anti-VEGF therapy with bowel perforation and impaired healing (also relevant to anastomotic decisions in patients on such agents). Finally, caecal perforation proximal to a left colon cancer is a classic mechanism question — the answers "sterocoral" or "ischaemic" score nothing unless linked to the obstructing distal lesion.
Frequently asked questions
Why does a distal colon cancer cause caecal perforation?
Because a competent ileocaecal valve converts the obstructed colon into a closed loop; rising intraluminal pressure stretches and ischaemically perforates the caecum, the thinnest, widest part of the large bowel.
Which operation is standard for perforated rectosigmoid cancer?
Hartmann's procedure — resection of the perforated segment with an end colostomy and closure or defunctioning of the rectal stump — avoiding an anastomosis in a contaminated field.
How does lymphoma change the management of bowel perforation?
The surgical role is limited to controlling the perforation and securing tissue; definitive treatment is chemotherapy, and lymphoma may perforate during treatment-induced tumour regression, so extensive resection is avoided.
Why does bevacizumab increase perforation risk?
Anti-vascular endothelial growth factor therapy impairs microvascular repair and wound healing in the bowel wall, predisposing to perforation — a recognised oncological emergency in patients on the drug.
When is non-operative management acceptable for malignant perforation?
In end-stage disease where intervention would not improve quality or duration of life, or with a sealed, localised perforation drained percutaneously — decisions made with oncology, palliative care and the family.